Question 1

What is the catalog number for ADAM17 (ADAM Metallopeptidase Domain 17, CD156b, MGC71942, TACE, cSVP)?

Accepted Answer

The catalog number for ADAM17 (ADAM Metallopeptidase Domain 17, CD156b, MGC71942, TACE, cSVP) is 243089.

Question 2

What sizes are available for ADAM17 (ADAM Metallopeptidase Domain 17, CD156b, MGC71942, TACE, cSVP)?

Accepted Answer

ADAM17 (ADAM Metallopeptidase Domain 17, CD156b, MGC71942, TACE, cSVP) is available in the following size(s): 200 µL.

Question 3

Is ADAM17 (ADAM Metallopeptidase Domain 17, CD156b, MGC71942, TACE, cSVP) in stock?

Accepted Answer

ADAM17 (ADAM Metallopeptidase Domain 17, CD156b, MGC71942, TACE, cSVP) is currently made to order / not held in immediate stock. Contact us for lead time.

Question 4

What documentation should I request if this product is used for a regulated or intellectual-property-sensitive application?

Accepted Answer

If the product is subject to intellectual property protections, we’ll advise on any MTA or usage restrictions before shipping. Let us know your intended end use so we can confirm what’s required upfront.

Question 5

Is this antibody conjugated?

Accepted Answer

Conjugation status, such as unconjugated, HRP, FITC, or biotin, is specified in the product name and confirmed on the datasheet.

Question 6

What is the sensitivity of this ELISA kit?

Accepted Answer

Assay sensitivity, including the minimum detectable dose, is listed on the datasheet. Kits that are assembled on order typically ship within 2-4 weeks.

ADAM17 (ADAM Metallopeptidase Domain 17, CD156b, MGC71942, TACE, cSVP)

Product Specifications

Clonality

Frequently Asked Questions

Explore Other Products

Anti-Lck Antibody Picoband® (PE Conjugate)

AMACR / p504S (Prostate Cancer Marker) (AMACR/1864), CF594 conjugate, 0.1mg/mL

CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), CF640R conjugate, 0.1mg/mL

Melanoma Marker (KBA.62), CF647 conjugate, 0.1mg/mL

VEGF (Vascular Endothelial Growth Factor) (VG1), CF568 conjugate, 0.1mg/mL

PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2743), CF640R conjugate, 0.1mg/mL